MK8776 attenuates radiation-induced PD-L1 expression
Cell-based study · U2OS osteosarcoma cells; U2OS, H1299 lung cancer and DU145 prostate cancer cells for surface PD-L1 [1]
At 50 nM, MK8776 reduced radiation-induced PD-L1 mRNA in U2OS and surface PD-L1 in three cancer cell lines. The protein blot provides qualitative supporting evidence. These expression endpoints support involvement of CHK1 signaling; they do not establish biochemical selectivity, immune-cell function or antitumor efficacy.
| Endpoint | Reported result | Reference |
|---|---|---|
| PD-L1 mRNA in U2OS after 10 Gy, with or without MK8776 | Relative mRNA level Reduced with MK8776 versus irradiation alone; mean with s.d. of three independent experiments; Figure 2 has no numerical bar labels; no values digitized | [1] |
| Cell-surface PD-L1 in U2OS, H1299 and DU145 after 10 Gy, with or without MK8776 | Mean fluorescence intensity Reduced with MK8776 versus irradiation alone in all three models; mean with s.d. of three independent experiments; Figure 2 has no numerical bar labels; no values digitized | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- MK8776 50 nM
- Exposure duration
- Added 30 min before irradiation; endpoints at 48 h after irradiation
- Method
- Cell-culture treatment with or without 10 Gy X-rays
- Vehicle
- DMSO control labeled in Figure 2f–g; final solvent percentage not specified in the reviewed methods
- Co-treatment
- 10 Gy X-ray irradiation; nonirradiated DMSO and irradiated DMSO controls; UCN-01 tested as a separate CHK1-inhibitor comparator
- Reported limits
- No lot number, salt specification or analytical stereochemical validation in reviewed drug methods; Figure 2 has no numerical bar labels. No MK8776 IC50 measured in this experiment.
Methods and source locations
Compound reported in the paper: MK8776 (SCH 900776); Compound label in the paper: Chk1i (MK)
Evidence for the named research compound in these cancer-cell conditions; no validation of the current Adooq lot or of clinical activity.
Figure 2e–g and caption; Results: PD-L1 upregulation requires ATM/ATR/Chk1 activity after DSBs; Methods: Cell culture, irradiation and drug treatment; Quantification of mRNA expression levels by real-time PCR; Surface flow cytometry analysis of PD-L1
PD-L1 mRNA in U2OS after 10 Gy, with or without MK8776: Real-time PCR, 48 h after irradiation; normalized to GAPDH. — Figure 2f and caption; Methods: Quantification of mRNA expression levels by real-time PCR
Cell-surface PD-L1 in U2OS, H1299 and DU145 after 10 Gy, with or without MK8776: Flow cytometry with PD-L1-APC; propidium-iodide-negative cells analyzed at 48 h. — Figure 2g and caption; Methods: Surface flow cytometry analysis of PD-L1